Dan Rhon

I study how we prevent & better manage MSK disorders in DHA/DoD/ @MilitaryHealth /MDR Consultant/Professor @USUhealthsci /Tweets 💯 Me! Runs @clinicrelevant

[Joshua Zadro @zadro_josh]

We developed a decision aid to help people with femoroacetabular impingement syndrome choose between surgery and non-surgical options @msk_health

Mixed methods development described here https://t.co/GpX8PZH4Ls

Decision aid (+ others) can be found here https://t.co/za4ruV1946

[Dan Rhon @danrhon]

@DrDunning @HandoBen31592 @JoshClelandPT

[Dan Rhon @danrhon]

Link to article: https://t.co/TKtooFVoGP

[Dan Rhon @danrhon]

Conflict of interest reporting in trials/guidelines on CSI for knee #osteoarthritis
29% of trials & 14.3% of guidelines had no COI statement. 13.3% of trials & 42.9% of guidelines reported a COI. Discrepancies existed between disclosures in manuscripts vs public databases.

[Dan Rhon @danrhon]

@DrDunning @HandoBen31592 @JoshClelandPT Last post- I like discussion but not sure this is productive. 1 difference is many of my trials have been null. Disappointing. I’m not benefiting from results. ALL your trials show the treatment u train people in is superior. That’s amazing -good on you! I haven’t been as lucky

[Dan Rhon @danrhon]

@DrDunning @HandoBen31592 @JoshClelandPT Not publishing exact duration of symptoms doesn’t invalidate findings though? These were all care-seeking pnts. I’ve published approx same number of trials, including in NEJM, Annals of IM, & JAMA, & duration of symptoms not always required. I agree is nice to have when possible.

[Dan Rhon @danrhon]

@DrDunning @HandoBen31592 @JoshClelandPT I don’t disagree tht should have been disclosed. I’m surprised it wasn’t. I was more speaking about my role, & what I should have disclosed? 99% of clinics research pubs include authors w academic positions - that alone seems bit of stretch to invalidate findings of this trial?

[Dan Rhon @danrhon]

@DrDunning @HandoBen31592 @JoshClelandPT I’m not on the editorial board. Never have been. Would be news to me https://t.co/msWfYPbqvA
There aren’t methodological flaws & cloudy statistical methods. I didn’t find those points convincing. There are wrong approaches, but rarely 1 right way. Nothing wrong w his approach

[Dan Rhon @danrhon]

@DrDunning @HandoBen31592 @JoshClelandPT Maybe, but even if so that would be based on publication count (yes/no) & not based on whether the trial results were null. I’d have absolutely nothing to gain whether this showed the intervention to be superior, inferior, or no different. What should I be disclosing exactly?

[Dan Rhon @danrhon]

@DrDunning @HandoBen31592 @JoshClelandPT Also, as far as I’m aware, I’ve never been on the JOSPT editorial board or held an AE position with JOSPT. I am a reviewer, but that’s quite different. I’m also not sure what I would have to gain from these results if I were…?

[Dan Rhon @danrhon]

@DrSethPT @JakeMagel @Retlouping @marklaslett_NZ @mismeg77 Not that I’m aware of, but agree it would be an interesting place to look further into.

[Derek Griffin @DerekGriffin86]

This is a really cool study from @MaxRavnMerkel et al. of the clinical & pathological features of early/late tendinopathy. There are likely implications for rx i.e a focus of calming down the tendon (early) vs more traditional resistance training (late).
https://t.co/neelXJQUDa

[Dan Rhon @danrhon]

When science is published and disseminated in non-traditional manner, without peer review, there are implications to consider - an example from the telehealth literature: https://t.co/y1vGlHD2eO
@JOSPT
@awmcdevittDPT @JakeMagel @mismeg77

[Dan Rhon @danrhon]

Much of the evidence driving policy for the use of telehealth for musculoskeletal rehabilitation is riddled with conflicts of interest - we need better transparency. @awmcdevittDPT @JakeMagel @mismeg77 https://t.co/Vs42z8aNky

[Dan Rhon @danrhon]

@PTJournal just published paper from @KaitlynFosterPT's PhD dissertation, looking at role of exercise for LBP in preventing subsequent lower extremity! Also, greater doses of exercise were associated w lower risk of subsequent LE injury! https://t.co/THaN1e4zzD 👏

[Ruth Chimenti @RuthChimenti]

We're hiring! Join the Carl R. Darnall Army Medical Center as a Research Physical Therapist and help advance military medicine. 
📍 Fort Hood, TX
🏥 Full-time | $90K–$110K
Apply now  👉 https://t.co/7Xbix08S31
#PhysicalTherapy #MilitaryMedicine #ResearchJobs #GenevaFoundation

[Dan Rhon @danrhon]

@ross_prager @MushtaqBilalPhD Also more journals seem to be adopting the “Your Paper, Your Way” submissions w no formatting requirements, but not nearly enough. What if you market to journals, & they use this to properly format any loose unformatted docs we authors submit? win-win

[Dan Rhon @danrhon]

@ross_prager @MushtaqBilalPhD Sounds great! Can’t wait to see! You could offer 500 manuscript reformats/month & would be no different than 10. No one will reach that. My volume is maybe 4-8 per year where I’m corresponding author. More as co-author, but I wouldn’t need this then. Would def use if cost right.

[Dan Rhon @danrhon]

@MushtaqBilalPhD Plus the reformatting is only a part of a resubmission. Part of the pain of resubmission is time to re-add all co-authors to submission platform, resigning all journal specific COIs & agreements, adding in all the admin info to the platform, that supports the submission, etc.

[Dan Rhon @danrhon]

@MushtaqBilalPhD The idea is fantastic! The business model not so much. Starting level allows for 10 manuscript reformats/month ($468/yr fee). There is a very, very tiny proportion of the market that produces that volume. I imagine much more uptake if they also offered a per/manuscript option.